NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
企業コードNPCE
会社名Neuropace Inc
上場日Apr 22, 2021
最高経営責任者「CEO」Mr. Joel D. Becker
従業員数184
証券種類Ordinary Share
決算期末Apr 22
本社所在地455 N. Bernardo Avenue
都市MOUNTAIN VIEW
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94043
電話番号16502372700
ウェブサイトhttps://www.neuropace.com/
企業コードNPCE
上場日Apr 22, 2021
最高経営責任者「CEO」Mr. Joel D. Becker
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし